PAREXEL, UCB partner to provide clinical development services worldwide

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by UCB, a global biopharmaceutical company, to provide clinical development services worldwide. PAREXEL will work with UCB to drive innovation and accelerate development, as well as to increase productivity and cost effectiveness.

The agreement is effective for all of UCB's new clinical study programs on a global basis. Through the strategic partnership, UCB will receive the benefits of PAREXEL's proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform. UCB will also leverage PAREXEL's consulting expertise in regulatory affairs and commercialization.

"Through the strategic partnership, PAREXEL will assist UCB to improve efficiency and cost effectiveness, and support increased opportunity for innovation, collaboration and the continuous improvement of quality and services -- helping us to deliver new medicines to patients worldwide," said Iris Loew-Friedrich, Executive Vice President and Chief Medical Officer of UCB. "PAREXEL will be instrumental in helping UCB expand our global drug development activities including in Asia."

"As a leader in the strategic partnership model, we look forward to providing UCB with best practices to bolster the success of their development efforts.  Leveraging our global resources and worldwide infrastructure, as well as the depth and breadth of our expertise, we look forward to working collaboratively with UCB to deliver customized, innovative solutions to achieve their goals," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.

By partnering with PAREXEL, biopharmaceutical companies of all sizes, including mid-tier companies, can leverage the Company's global resources, quality standards, extensive therapeutic expertise and broad-based experience to create significant value, drive performance, and accomplish their development and commercialization goals.

PAREXEL provides a unique combination of regulatory and commercialization consulting, clinical development expertise, and integrated eClinical technologies from Perceptive Informatics to achieve results for ever more complex development programs. The Company leverages its established global footprint in 52 countries to provide the right experts in the right geographical locations for any aspect or phase of designing and executing clinical trials.